创新药概念反复走强，创新药ETF天弘（517380）窄幅震荡，恒瑞医药23日登陆港交所

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a resurgence, with notable performances from companies like Sanofi and the launch of Heng Rui Pharmaceutical's H-shares in Hong Kong [1][3] - The Tianhong Innovative Drug ETF has seen a continuous increase for seven days, indicating strong investor interest in the innovative drug sector [1][2] - Heng Rui Pharmaceutical has set its H-share issuance price at HKD 44.05, which is the upper limit of the expected price, reflecting positive market sentiment towards A-share companies listing in Hong Kong [1] Group 2 - The Biopharmaceutical ETF closely tracks the Guozheng Biopharmaceutical Index, which includes the top 30 companies in the biopharmaceutical industry based on market capitalization and liquidity [2] - The Tianhong Innovative Drug ETF tracks the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug 50 Index, which selects 50 leading innovative drug companies across three markets [2] - The innovative drug sector is expected to remain a core focus for the pharmaceutical industry, supported by policy backing and increasing global competitiveness [3]